Cardiac Arrhythmia Suppression Trial

Cardiac Arrhythmia Suppression Trial
Name	Cardiac Arrhythmia Suppression Trial
Acronym	CAST
Year	1989
Phase	III
Condition	Ventricular arrhythmia
Interventions	Encainide, flecainide, moricizine
Sponsor	National Heart, Lung, and Blood Institute
Location	United States, Canada

Cardiac Arrhythmia Suppression Trial was a landmark randomized clinical trial that evaluated antiarrhythmic drug therapy for patients with prior myocardial infarction and asymptomatic or mildly symptomatic ventricular premature beats. The trial unexpectedly demonstrated increased mortality with class I antiarrhythmic agents, prompting changes in clinical practice and regulatory oversight. The results influenced cardiology, pharmacology, and public health policy across academic institutions, professional societies, and regulatory agencies.

Background

The trial grew from research on post-myocardial infarction care at institutions such as Johns Hopkins Hospital, Mayo Clinic, Cleveland Clinic, Massachusetts General Hospital, Stanford Health Care, University of Pennsylvania Health System, Mount Sinai Hospital (New York), Brigham and Women's Hospital, UCLA Health, and Columbia University Irving Medical Center. Key figures included investigators affiliated with the National Heart, Lung, and Blood Institute, American Heart Association, European Society of Cardiology, Royal College of Physicians, and academic departments at Harvard Medical School, Yale School of Medicine, University of California, San Francisco School of Medicine, University of Toronto Faculty of Medicine, and McGill University Faculty of Medicine. The study addressed questions raised by earlier observational work at centers like Baylor College of Medicine and experimental pharmacology studies at Mount Sinai School of Medicine and Weill Cornell Medicine. Contemporary trials and guidelines from the World Health Organization, Food and Drug Administration, European Medicines Agency, British Heart Foundation, and Canadian Cardiovascular Society formed the regulatory and ethical context. Influential clinicians and researchers involved or contemporaries included figures associated with Framingham Heart Study, Olmsted County, Duke University School of Medicine, Vanderbilt University Medical Center, Johns Hopkins Bloomberg School of Public Health, University College London, Karolinska Institutet, Imperial College London, University of Oxford, University of Cambridge, King's College London, University of Edinburgh, University of Glasgow, University of Birmingham, University of Manchester, University of Zurich, University of Basel, University of Geneva, University of Milan, University of Barcelona, University of Heidelberg, University of Freiburg, University of Munich, University of Vienna, Technion – Israel Institute of Technology, Tel Aviv Sourasky Medical Center, Sheba Medical Center, Seoul National University Hospital, Peking University First Hospital, Shanghai Jiao Tong University School of Medicine, National University of Singapore Yong Loo Lin School of Medicine, University of Sydney, University of Melbourne, Monash University, University of Auckland, University of Cape Town, University of São Paulo, University of Buenos Aires, Pontifical Catholic University of Chile, University of Chile, King Saud University, Cairo University, All India Institute of Medical Sciences, New Delhi, Christian Medical College, Vellore, St. George's University Hospitals NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust, The Royal Marsden NHS Foundation Trust, Addenbrooke's Hospital, and Royal Brompton Hospital.

Study Design and Methods

The randomized, double‑blind, placebo‑controlled multicenter trial evaluated suppression of ventricular ectopy using class I antiarrhythmics: encapsulated encainide, flecainide, and moricizine. Enrollment criteria derived from post‑infarction cohorts characterized at centers such as Framingham Heart Study and Olmsted County and checked against registries at Duke University Hospital and Mayo Clinic. Primary endpoints combined arrhythmic and all‑cause mortality, with secondary analyses incorporating sudden cardiac death metrics tracked in collaboration with the National Institutes of Health, Centers for Disease Control and Prevention, World Health Organization, and national vital statistics agencies in United States, Canada, United Kingdom, Sweden, Norway, Denmark, Finland, Germany, France, Italy, Spain, Australia, New Zealand, Japan, South Korea, China, India, Brazil, Argentina, and South Africa. Statistical oversight involved biostatisticians linked to Johns Hopkins Bloomberg School of Public Health, Harvard T.H. Chan School of Public Health, University of Washington School of Public Health, Columbia University Mailman School of Public Health, and Yale School of Public Health. Trial governance referenced ethical frameworks from Declaration of Helsinki, regulations influenced by the Food and Drug Administration Modernization Act, and data monitoring concepts promoted by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Adjudication committees included cardiologists from American College of Cardiology, European Society of Cardiology, Canadian Cardiovascular Society, Japanese Circulation Society, and Chinese Society of Cardiology.

Results

STOPPING the trial early after planned interim analyses revealed higher mortality among treatment arms challenged prevailing assumptions from electrophysiology studies at Stanford University School of Medicine, University of California, San Francisco, Mayo Clinic, Cleveland Clinic, and Mount Sinai Hospital. All‑cause mortality and arrhythmic death rates were increased for patients randomized to encainide and flecainide compared with placebo, whereas data for moricizine were more complex and required subgroup assessment. The findings echoed prior safety signals in pharmacovigilance databases maintained by the Food and Drug Administration, Health Canada, Medicines and Healthcare products Regulatory Agency, European Medicines Agency, and national pharmacovigilance centers in France, Germany, Italy, Spain, Sweden, Norway, and Finland. Data presentations at meetings hosted by American Heart Association, European Society of Cardiology, Heart Rhythm Society, North American Society of Pacing and Electrophysiology, International Society for Heart Research, and World Congress of Cardiology catalyzed rapid dissemination.

Interpretation and Clinical Impact

The trial contradicted mechanistic expectations from cardiac electrophysiology research at Beth Israel Deaconess Medical Center, University of Michigan Health System, Vanderbilt University Medical Center, University of Pennsylvania Health System, and Emory University Hospital, emphasizing that suppression of surrogate markers such as ventricular premature beats did not equate to improved survival. Clinical guidelines from American College of Cardiology, American Heart Association, European Society of Cardiology, Canadian Cardiovascular Society, Japanese Circulation Society, and Heart Rhythm Society were revised to recommend caution or avoidance of class I agents in post‑infarction patients. Regulatory actions by the Food and Drug Administration, Health Canada, Medicines and Healthcare products Regulatory Agency, and European Medicines Agency affected labeling, marketing, and clinical use of the implicated drugs. Educational programs at Harvard Medical School, Johns Hopkins School of Medicine, Mayo Clinic Alix School of Medicine, Stanford Medicine, Yale School of Medicine, UCSF School of Medicine, and Columbia University Vagelos College of Physicians and Surgeons incorporated the trial as a paradigm case in evidence‑based medicine curricula.

Controversies and Criticism

Critics cited trial limitations discussed in forums at American Heart Association Scientific Sessions, European Society of Cardiology Congress, Heart Rhythm Society Scientific Sessions, World Congress of Cardiology, and editorials in journals associated with The Lancet, The New England Journal of Medicine, Journal of the American College of Cardiology, Circulation, and European Heart Journal. Debates involved interpretation of subgroup analyses, generalizability to patients without prior myocardial infarction identified at centers like Baylor College of Medicine and Duke University Hospital, and implications for class III antiarrhythmics developed at Pfizer, Boehringer Ingelheim, Merck & Co., GlaxoSmithKline, AstraZeneca, Novartis, Bristol-Myers Squibb, Sanofi, Eli Lilly and Company, Roche, and Johnson & Johnson. Methodological critiques referenced biostatistical practices taught at Harvard T.H. Chan School of Public Health, Johns Hopkins Bloomberg School of Public Health, University of Washington School of Public Health, Columbia University Mailman School of Public Health, and Yale School of Public Health. Legal and regulatory debates engaged stakeholders including the Food and Drug Administration, European Medicines Agency, Health Canada, plaintiffs' bar in United States, and healthcare payers such as Centers for Medicare & Medicaid Services and national health services in United Kingdom and Canada.

Legacy and Subsequent Research

The trial reshaped antiarrhythmic drug development and study design worldwide at academic centers and companies tied to University of Oxford, University of Cambridge, Imperial College London, Karolinska Institutet, University of Toronto, McMaster University, Monash University, University of Melbourne, National University of Singapore, Seoul National University, Peking University, and University of São Paulo. It stimulated research into implantable cardioverter‑defibrillators at centers like Cleveland Clinic, Mayo Clinic, Johns Hopkins Hospital, Brigham and Women's Hospital, and Vanderbilt University Medical Center, and trials such as those sponsored by National Heart, Lung, and Blood Institute and cooperative groups including NIH Clinical Center and multicenter consortia. Follow‑up studies examined class III agents, rate versus rhythm strategies in atrial fibrillation trials from AFFIRM investigators, catheter ablation trials emerging from Stanford University, Baylor College of Medicine, and Montreal Heart Institute, and long‑term outcomes research tied to registries like Framingham Heart Study, Get With The Guidelines, and national cardiovascular data sets in United States, United Kingdom, Canada, Sweden, and Australia. The trial remains a canonical case in clinical trial ethics, risk‑benefit assessment, and regulatory science taught at Harvard T.H. Chan School of Public Health and Johns Hopkins Bloomberg School of Public Health.

Category:Cardiology clinical trials